

# Jorge Plutzky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5838968/publications.pdf>

Version: 2024-02-01

81  
papers

6,090  
citations

134610

34  
h-index

81351

76  
g-index

85  
all docs

85  
docs citations

85  
times ranked

9613  
citing authors

#	ARTICLE	IF	CITATIONS
1	Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. <i>American Heart Journal</i> , 2022, 243, 15-27.	1.2	8
2	The Aging Aorta: Are We Only as Old as Our Endothelium?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 172-174.	1.1	1
3	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	1.2	23
4	Impact of coronary artery calcium testing on patient management. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 303-308.	0.7	5
5	Perivascular Fibrosis Is Mediated by a KLF10-IL-9 Signaling Axis in CD4+ T Cells. <i>Circulation Research</i> , 2022, 130, 1662-1681.	2.0	6
6	Relationship Between Risk of Atherosclerotic Cardiovascular Disease, Inflammation, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	4
7	Shortwave infrared spatial frequency domain imaging for non-invasive measurement of tissue and blood optical properties. <i>Journal of Biomedical Optics</i> , 2022, 27, .	1.4	7
8	Atherosclerotic cardiovascular disease risk and elevated lipoprotein(a) among young adults with myocardial infarction: The Partners YOUNG-MI Registry. <i>European Journal of Preventive Cardiology</i> , 2021, 28, e12-e14.	0.8	8
9	Digital Care Transformation. <i>Circulation</i> , 2021, 143, 507-509.	1.6	40
10	Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. <i>American Heart Journal</i> , 2021, 235, 104-112.	1.2	82
11	Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations. <i>Current HIV/AIDS Reports</i> , 2021, 18, 271-279.	1.1	24
12	Association of Socioeconomic Disadvantage With Long-term Mortality After Myocardial Infarction. <i>JAMA Cardiology</i> , 2021, 6, 880.	3.0	36
13	BRD2 regulation of sigma-2 receptor upon cholesterol deprivation. <i>Life Science Alliance</i> , 2021, 4, e201900540.	1.3	13
14	Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins. <i>American Journal of Preventive Cardiology</i> , 2021, 8, 100278.	1.3	14
15	Retinoids Repress Human Cardiovascular Cell Calcification With Evidence for Distinct Selective Retinoid Modulator Effects. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 656-669.	1.1	17
16	Intact vitamin A transport is critical for cold-mediated adipose tissue browning and thermogenesis. <i>Molecular Metabolism</i> , 2020, 42, 101088.	3.0	14
17	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. <i>American Heart Journal</i> , 2020, 229, 61-69.	1.2	137
18	Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2020, 5, 1430.	3.0	62

#	ARTICLE	IF	CITATIONS
19	Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry. <i>Diabetes Care</i> , 2020, 43, 1843-1850.	4.3	27
20	Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease. <i>JAMA Cardiology</i> , 2020, 5, 1182.	3.0	59
21	Epigenetic Therapeutics for Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1557.	3.8	3
22	BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs. <i>Circulation Research</i> , 2020, 126, 1190-1208.	2.0	88
23	To fast or not to fast: Lipid measurement and cardiovascular disease risk estimation in rural sub-Saharan Africa. <i>Journal of Global Health</i> , 2020, 10, 010407.	1.2	6
24	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM $\alpha$ ) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	2.7	104
25	The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation. <i>Cellular Signalling</i> , 2019, 61, 20-29.	1.7	20
26	Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2439-2450.	1.2	69
27	Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration. <i>Current Diabetes Reports</i> , 2019, 19, 157.	1.7	7
28	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. <i>European Heart Journal</i> , 2019, 40, 2907-2919.	1.0	32
29	A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes. <i>Global Heart</i> , 2019, 14, 215.	0.9	24
30	Lipids in RA: Is Less Not Necessarily More?. <i>Current Rheumatology Reports</i> , 2018, 20, 8.	2.1	13
31	Predictors of a successful statin reattempt after an adverse reaction. <i>Journal of Clinical Lipidology</i> , 2018, 12, 643-651.	0.6	7
32	BET bromodomain proteins regulate enhancer function during adipogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2144-2149.	3.3	65
33	Cardiovascular Risk and Statin Eligibility of Young Adults After an MI. <i>Journal of the American College of Cardiology</i> , 2018, 71, 292-302.	1.2	145
34	Adiponectin concentration data improve the estimation of atherosclerotic risk in normal and in overweight subjects. <i>Clinical Endocrinology</i> , 2018, 88, 388-396.	1.2	4
35	Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 130-133.	1.6	7
36	Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2389-2398.	2.2	19

#	ARTICLE	IF	CITATIONS
37	Distribution and Performance of Cardiovascular Risk Scores in a Mixed Population of HIV-Infected and Community-Based HIV-Uninfected Individuals in Uganda. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 458-464.	0.9	15
38	Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes. <i>Annals of Internal Medicine</i> , 2017, 167, 221.	2.0	80
39	Adipocyte arrestin domain-containing 3 protein ( <i>Arrdc3</i> ) regulates uncoupling protein 1 ( <i>Ucp1</i> ) expression in white adipose independently of canonical changes in $\beta^2$ -adrenergic receptor signaling. <i>PLoS ONE</i> , 2017, 12, e0173823.	1.1	8
40	Brown Fat and Browning for the Treatment of Obesity and Related Metabolic Disorders. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 12.	1.8	180
41	Epigenetic Changes in Diabetes and Cardiovascular Risk. <i>Circulation Research</i> , 2016, 118, 1706-1722.	2.0	98
42	Inhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in <i>ApoE<sup>-/-</sup></i> mice. <i>International Journal of Cardiology</i> , 2016, 223, 428-432.	0.8	15
43	Risk factors for lack of statin therapy in patients with diabetes and coronary artery disease. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1406-1413.	0.6	7
44	Extensive metabolic disorders are present in <i>APC<sup>min</sup></i> tumorigenesis mice. <i>Molecular and Cellular Endocrinology</i> , 2016, 427, 57-64.	1.6	15
45	Super enhancers at the <i>miR-146a</i> and <i>miR-155</i> genes contribute to self-regulation of inflammation. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2016, 1859, 564-571.	0.9	45
46	Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0155228.	1.1	37
47	Association of monocyte tumor necrosis factor $\alpha$ expression and serum inflammatory biomarkers with walking impairment in peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2015, 61, 155-161.	0.6	44
48	Emerging Epigenetic Maps in Atherosclerosis. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 573-575.	5.1	0
49	Diabetes and Cardiovascular Disease in Older Adults: Current Status and Future Directions. <i>Diabetes</i> , 2014, 63, 2578-2589.	0.3	185
50	Impact of pre-diabetes on heart transplant outcomes in patients with advanced heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 215-217.	0.3	3
51	Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 399-405.	1.2	75
52	NF- $\kappa$ B Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis. <i>Molecular Cell</i> , 2014, 56, 219-231.	4.5	507
53	Retinaldehyde dehydrogenase 1 deficiency inhibits PPAR $\gamma$ -mediated bone loss and marrow adiposity. <i>Bone</i> , 2014, 67, 281-291.	1.4	8
54	(Mis)interpreting studies on the adverse effects of statins. <i>BMJ, The</i> , 2014, 348, g3652-g3652.	3.0	2

#	ARTICLE	IF	CITATIONS
55	BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure. <i>Cell</i> , 2013, 154, 569-582.	13.5	346
56	Retinaldehyde Dehydrogenase 1 Coordinates Hepatic Gluconeogenesis and Lipid Metabolism. <i>Endocrinology</i> , 2012, 153, 3089-3099.	1.4	94
57	Retinaldehyde dehydrogenase 1 regulates a thermogenic program in white adipose tissue. <i>Nature Medicine</i> , 2012, 18, 918-925.	15.2	176
58	Macrovascular Effects and Safety Issues of Therapies for Type 2 Diabetes. <i>American Journal of Cardiology</i> , 2011, 108, 25B-32B.	0.7	35
59	The PPAR-RXR Transcriptional Complex in the Vasculature. <i>Circulation Research</i> , 2011, 108, 1002-1016.	2.0	138
60	Hyperlipidemia After Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2010, 116, 3457-3457.	0.6	0
61	Expansion and contraction: the mighty, mighty fatty acid. <i>Nature Medicine</i> , 2009, 15, 618-619.	15.2	10
62	Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR-RXR complex. <i>FEBS Letters</i> , 2008, 582, 32-38.	1.3	180
63	Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPAR. <i>Diabetes and Vascular Disease Research</i> , 2007, 4, S12-S14.	0.9	9
64	Peroxisome Proliferator-Activated Receptors and the Endothelium. , 2007, , 796-805.		0
65	Retinaldehyde represses adipogenesis and diet-induced obesity. <i>Nature Medicine</i> , 2007, 13, 695-702.	15.2	346
66	A Cardiologist's Perspective on Cardiometabolic Risk. <i>American Journal of Cardiology</i> , 2007, 100, S3-S6.	0.7	23
67	Inflammation in Atherosclerosis and Diabetes Mellitus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2004, 5, 255-259.	2.6	35
68	The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis. <i>American Journal of Cardiology</i> , 2003, 92, 34-41.	0.7	70
69	MEDICINE: PPARs as Therapeutic Targets: Reverse Cardiology?. <i>Science</i> , 2003, 302, 406-407.	6.0	86
70	Diabetes as a vascular disease. Dyslipidemia as a target. <i>Postgraduate Medicine</i> , 2003, 113, 15-23.	0.9	0
71	Diabetic Macrovascular Disease. <i>Circulation</i> , 2002, 106, 2760-2763.	1.6	121
72	Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. <i>Journal of Diabetes and Its Complications</i> , 2002, 16, 401-415.	1.2	72

#	ARTICLE	IF	CITATIONS
73	PPAR $\alpha$ Activators Inhibit Tissue Factor Expression and Activity in Human Monocytes. <i>Circulation</i> , 2001, 103, 213-219.	1.6	177
74	Peroxisome Proliferator-Activated Receptors (PPARs) and Their Role in the Vessel Wall: Possible Mediators of Cardiovascular Risk?. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2001, 8, 203-210.	3.1	25
75	Statins for Stroke: The Second Story?. <i>Circulation</i> , 2001, 103, 348-350.	1.6	23
76	Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: Emerging insights for evolving paradigms. <i>Current Atherosclerosis Reports</i> , 2000, 2, 327-335.	2.0	77
77	PPAR $\beta$ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 546-551.	1.1	355
78	PPAR $\alpha$ Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial Cells. <i>Circulation</i> , 1999, 99, 3125-3131.	1.6	584
79	Effect of lipid-lowering therapy on vasomotion and endothelial function. <i>Current Cardiology Reports</i> , 1999, 1, 238-243.	1.3	14
80	Peroxisome Proliferator-Activated Receptor Gamma Activators Inhibit Gene Expression and Migration in Human Vascular Smooth Muscle Cells. <i>Circulation Research</i> , 1998, 83, 1097-1103.	2.0	565
81	PPARs in Atherosclerosis. , 0, , 401-417.		0